SG11201808829VA - Tdp-43 mitochondrial localization inhibitor for the treatment of neurodegenerative disease - Google Patents
Tdp-43 mitochondrial localization inhibitor for the treatment of neurodegenerative diseaseInfo
- Publication number
- SG11201808829VA SG11201808829VA SG11201808829VA SG11201808829VA SG11201808829VA SG 11201808829V A SG11201808829V A SG 11201808829VA SG 11201808829V A SG11201808829V A SG 11201808829VA SG 11201808829V A SG11201808829V A SG 11201808829VA SG 11201808829V A SG11201808829V A SG 11201808829VA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- tdp
- ohio
- april
- pct
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Neurosurgery (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Hospice & Palliative Care (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Rheumatology (AREA)
- Rehabilitation Therapy (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Epidemiology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662319580P | 2016-04-07 | 2016-04-07 | |
| US201662328484P | 2016-04-27 | 2016-04-27 | |
| PCT/US2017/026675 WO2017177178A1 (en) | 2016-04-07 | 2017-04-07 | Tdp-43 mitochondrial localization inhibitor for the treatment of neurodegenerative disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201808829VA true SG11201808829VA (en) | 2018-11-29 |
Family
ID=60000683
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201808829VA SG11201808829VA (en) | 2016-04-07 | 2017-04-07 | Tdp-43 mitochondrial localization inhibitor for the treatment of neurodegenerative disease |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US11124553B2 (https=) |
| EP (1) | EP3440094B1 (https=) |
| JP (1) | JP2019513752A (https=) |
| KR (1) | KR20180132807A (https=) |
| CN (1) | CN109563130A (https=) |
| AU (1) | AU2017248353A1 (https=) |
| CA (1) | CA3020344A1 (https=) |
| SG (1) | SG11201808829VA (https=) |
| WO (1) | WO2017177178A1 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10906949B2 (en) | 2017-06-28 | 2021-02-02 | The Cleveland Clinic Foundation | Methods of treating spinal cord injury using a chondroitin sulfate proteoglycan (CSPG) reduction peptide (CRP) comprising a cell membrane penetrating domain, a CSPG binding domain, and a lysosome targeting domain |
| CN113683703B (zh) * | 2020-05-18 | 2023-08-15 | 中国人民解放军陆军军医大学第二附属医院 | 一种hTERT靶向物及其用途 |
| WO2021247893A1 (en) * | 2020-06-03 | 2021-12-09 | Yumanity Therapeutics, Inc. | Bicyclic heteroaromatic amide compounds and uses thereof |
| US20230250094A1 (en) * | 2020-07-15 | 2023-08-10 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Small molecule inhibitors of tdp-43 activity and uses thereof |
| CN114057858B (zh) | 2020-08-10 | 2023-03-21 | 上海瑞吉康生物医药有限公司 | 对引起神经变性和神经退行性疾病的蛋白聚集具有解聚作用的多肽 |
| KR102488166B1 (ko) | 2020-09-24 | 2023-01-13 | 재단법인대구경북과학기술원 | Ｈｄａｃ６의 ｔｄｐ－４３ 단백질병증 예방 또는 치료제로서의 용도 |
| JP6961278B1 (ja) * | 2021-03-10 | 2021-11-05 | 国立研究開発法人量子科学技術研究開発機構 | 生体試料中のｔｄｐ−４３を測定する方法及び装置 |
| CN113450336B (zh) * | 2021-07-01 | 2022-10-25 | 维柯基科技(上海)有限公司 | 一种多孔荧光微阵列图像的处理方法、装置、计算机设备及计算机可读存储介质 |
| KR20240133923A (ko) * | 2023-02-28 | 2024-09-05 | (주)케어젠 | 펩타이드 복합체를 유효성분으로 포함하는 항노화용 조성물 |
| KR102859015B1 (ko) | 2023-07-20 | 2025-09-12 | 충북대학교 산학협력단 | ｃＡｂｌ에 의한 ＴＤＰ４３의 특이적 인산화 분석을 통한 신경퇴행성 질환을 진단하는 방법 및 이를 이용한 신경퇴행성 질환의 치료제 스크리닝 방법 |
| WO2025152803A1 (zh) * | 2024-01-17 | 2025-07-24 | 四川大学 | 一种靶向traf6的多肽及其用途 |
| KR20260012942A (ko) * | 2024-07-19 | 2026-01-27 | 재단법인대구경북과학기술원 | 디히드로코스투스 락톤을 유효성분으로 포함하는 ｆｕｓ 또는 ｔｄｐ４３ 관련 질환의 예방 또는 치료용 조성물 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US5804604A (en) | 1989-12-21 | 1998-09-08 | Biogen, Inc. | Tat-derived transport polypeptides and fusion proteins |
| US5670617A (en) | 1989-12-21 | 1997-09-23 | Biogen Inc | Nucleic acid conjugates of tat-derived transport polypeptides |
| IE913929A1 (en) | 1990-11-13 | 1992-05-20 | Immunex Corp | Bifunctional selectable fusion genes |
| AU6953394A (en) | 1993-05-21 | 1994-12-20 | Targeted Genetics Corporation | Bifunctional selectable fusion genes based on the cytosine deaminase (cd) gene |
| US5858683A (en) * | 1996-08-30 | 1999-01-12 | Matritech, Inc. | Methods and compositions for the detection of cervical cancer |
| GB9718609D0 (en) | 1997-09-02 | 1997-11-05 | Imp College Innovations Ltd | Fusion protein |
| GB9723824D0 (en) * | 1997-11-11 | 1998-01-07 | Actinova Ltd | Cytostatic agents |
| US6841535B2 (en) | 2000-07-31 | 2005-01-11 | Active Motif | Peptide-mediated transfection agents and methods of use |
| US20040229837A1 (en) * | 2003-05-15 | 2004-11-18 | Yijuang Chern | Treatment of neurodegenerative diseases |
| CA2613749A1 (en) * | 2005-07-01 | 2007-01-11 | Arbor Vita Corporation | Methods and compositions for diagnosis and treatment of viral and bacterial infections |
| CA2671410C (en) * | 2006-12-06 | 2016-11-22 | Thomas Jefferson University | Peptide and treatment for hiv-1 infection |
| JP5798322B2 (ja) * | 2008-02-01 | 2015-10-21 | ワシントン ユニバーシティ イン セント ルイス | Ｔｄｐ−４３蛋白質症に関連した配列およびその使用法 |
| WO2010072228A1 (en) * | 2008-12-22 | 2010-07-01 | Xigen S.A. | Novel transporter constructs and transporter cargo conjugate molecules |
| US9926353B2 (en) * | 2011-07-19 | 2018-03-27 | New York University | Immunotherapeutic modulation of amyloidogenic disease using non-fibrillogenic, non-amyloidogenic polymerized proteins and peptides |
| EP2821504A4 (en) * | 2012-02-28 | 2016-02-17 | Univ Tokyo Nat Univ Corp | METHOD FOR DETERMINING A DISEASE RELATED TO TDP-43 CONCENTRATION IN CELLS |
| US9017672B2 (en) * | 2012-05-11 | 2015-04-28 | Immunicum Aktiebolag | Hexon Tat-PTD modified adenovirus and uses thereof |
| WO2013192298A1 (en) * | 2012-06-22 | 2013-12-27 | The Scripps Research Institute | Apoptosis biomarkers |
| GB201408255D0 (en) * | 2014-05-09 | 2014-06-25 | Immatics Biotechnologies Gmbh | Novel immunotherapy against several tumours of the blood, such as acute myeloid leukemia (AML) |
-
2017
- 2017-04-07 CN CN201780028382.0A patent/CN109563130A/zh active Pending
- 2017-04-07 AU AU2017248353A patent/AU2017248353A1/en not_active Abandoned
- 2017-04-07 EP EP17779936.8A patent/EP3440094B1/en not_active Not-in-force
- 2017-04-07 JP JP2018552826A patent/JP2019513752A/ja active Pending
- 2017-04-07 US US16/090,786 patent/US11124553B2/en active Active
- 2017-04-07 SG SG11201808829VA patent/SG11201808829VA/en unknown
- 2017-04-07 WO PCT/US2017/026675 patent/WO2017177178A1/en not_active Ceased
- 2017-04-07 CA CA3020344A patent/CA3020344A1/en not_active Abandoned
- 2017-04-07 KR KR1020187031919A patent/KR20180132807A/ko not_active Ceased
-
2021
- 2021-09-21 US US17/480,884 patent/US12129285B2/en active Active
-
2024
- 2024-10-28 US US18/928,949 patent/US20260116935A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20220220173A1 (en) | 2022-07-14 |
| AU2017248353A1 (en) | 2018-10-25 |
| CA3020344A1 (en) | 2017-10-12 |
| CN109563130A (zh) | 2019-04-02 |
| EP3440094A1 (en) | 2019-02-13 |
| US20190211070A1 (en) | 2019-07-11 |
| US11124553B2 (en) | 2021-09-21 |
| JP2019513752A (ja) | 2019-05-30 |
| WO2017177178A1 (en) | 2017-10-12 |
| KR20180132807A (ko) | 2018-12-12 |
| US12129285B2 (en) | 2024-10-29 |
| EP3440094B1 (en) | 2021-02-17 |
| EP3440094A4 (en) | 2019-03-20 |
| US20260116935A1 (en) | 2026-04-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201808829VA (en) | Tdp-43 mitochondrial localization inhibitor for the treatment of neurodegenerative disease | |
| SG11201908330PA (en) | Farnesoid x receptor agonists and uses thereof | |
| SG11201901063SA (en) | Therapeutic agents for neurodegenerative diseases | |
| SG11201908056QA (en) | Anti-par2 antibodies and uses thereof | |
| SG11201810525XA (en) | Anti-gitr antibodies and uses thereof | |
| SG11201811491YA (en) | Quinazoline and indole compounds to treat medical disorders | |
| SG11201809344QA (en) | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde | |
| SG11201806624XA (en) | Deposition of molybdenum thin films using a molybdenum carbonyl precursor | |
| SG11201909960UA (en) | Methods for improving memory and cognition and for treating memory and cognitive disorders | |
| SG11201811564QA (en) | Methods of treating ovarian cancer | |
| SG11201805579SA (en) | Recombinant igg fc multimers | |
| SG11201909856XA (en) | Mesenchymal lineage precursor or stem cells with enhanced immunosuppression | |
| SG11201809531SA (en) | BINDING MOLECULES SPECIFIC FOR FCγGAMMA RIIA AND USES THEREOF | |
| SG11201909011PA (en) | Niraparib compositions | |
| SG11201807784SA (en) | 3-desoxy derivative and pharmaceutical compositions thereof | |
| SG11201907583TA (en) | Methods for treating complement-mediated diseases and disorders | |
| SG11201810801QA (en) | Brain delivery protein | |
| SG11201909520VA (en) | Rna for treatment of autoimmune diseases | |
| SG11201908512YA (en) | Somatostatin modulators and uses thereof | |
| SG11201907369TA (en) | Anti-factor d antibodies and uses thereof | |
| SG11201809875VA (en) | Compositions and methods for treating spinal muscular atrophy | |
| SG11201909882SA (en) | Targeted neoepitope vectors and methods therefor | |
| SG11201807255YA (en) | Treatment of autoimmune diseases with combinations of rxr agonists and thyroid hormones | |
| SG11201807977XA (en) | Cancer therapy with an oncolytic virus combined with a checkpoint inhibitor | |
| SG11201805149XA (en) | Compositions comprising 15-hepe and methods of using the same |